not all great minds need to think alike: a case study from ... · not all great minds need to think...

WISE 9th May 2018

Louise ModisFiona ReedEmma KoppeBenjamin Verpaalen

Not all great minds need to think alike: A case study from the GSK Immunology Network

GSK Immunology Network - WISE May 2018 1

Focus on immunologyManipulating the immune system central to GSK’s R&D strategy

2GSK Immunology Network - WISE May 2018

Vaccines RespiratoryImmuno–Inflammation

Oncology

Leveraging our knowledge and assets between these therapy areas will be key to our success

The Immunology NetworkA unique industry-academia collaborative model

3

VisionTo enable GSK to lead in the field of immunology, to deliver the best science and the best medicines for patients by fully integrating immunology expertise between GSK and academia

OrganisationThree elements support the strategic objectives of the Immunology Network:

External Immunology Board (EIB)

Immunology Catalyst (IC)

Immunology Innovation Fund (IIF)

GSK Immunology Network - WISE May 2018

What are we trying to solve?The challenge of Pharma R&D productivity

4

Figure 1: Adapted from: Fernald, K.D.S., Weenen, T.C., Sibley, K.J., Claassen, E. (2013) Limits of Biotechnological Innovation. Technology and Innovation, 2013, 4, 168-178. Figure 2: Adapted from: Nesta – All together now: Improving cross-sector collaboration in the UK biomedical industry (2011). Report.

Figure 1: R&D expenditures versus New Chemical Entity (NCE) introductions

Pharma R&D productivityo How to better leverage scientific knowledge?o Open innovation: industry-academia collaborationso Win-win: increased impact of collaborative publications

Figure 2: Relative citation impact of biomedical publications


The GSK Immunology Catalyst

5

Breakthrough science

FOCUS AREAS

Breakthrough Science

TARGET

PROJECT

MOLECULE

MEDICINELeverage collective intelligence to identify & pursue the n extbreakthroughs that could be developed for therapeutic impa ctacross many different therapy areas

GSK scientists

External Immunology Board

Immunology Catalyst members

A new model for collaboration


The Immunology CatalystEvolution during set up

6

PI’s

% time 75% for 3yrs

Group 2 postdocs/PI % time 20 – 80% for 1-3yrs

Group 1 - 2 postdocs/PIGSK secondeesPhD students

Core Team

GSK Collaborations

Director

GSK Collaborations

Initial vision – Aug 2014

PI collaborations

In practice Feb 2016 - present


PI’s

Diversity within the Immunology CatalystGeographical, cultural, gender & career grade

7

Graduate Masters PhD

Scientific Leader

Principal Investigator

(PI)Professor

Manager DirectorFacilitator♀♂GSK Immunology Network - WISE May 2018

Motivations & AmbitionReasons for joining the Immunology Catalyst

8

An opportunity to learn how Industry

works

We need to work togetherThis is a win:win

setup

This brings the best of both worlds

together

I want to work for a world renowned

healthcare company

I want to feel like I’m making a difference

to human healthAccess to some of

the best technology/platforms

The opportunity to contribute to drug

discovery

It is exciting to combine corporate & academic expertise to generate

knowledge for the design of new medicines

I want to work with a world renowned

academic

I want to be part of an exciting novel

initiative

A fantastic opportunity to pursue fundamental

research in the company of drug discovery

scientists

I want to develop personally & scientifically

I want to explore Pharma/Industry

To build my network

I want to move country


Successfully building a diverse teamMultiple elements for consideration

9

Point contacts Host Labs

Collaboration Operations

RecruitmentEnabling Technologies

People Development


Measuring successRelinquishing control and empowering creativity

10

Project management methodology:o Key question: what does success look like?o Rigid scopeo Defined outcomes

Immunology Network: o Unpredictable variables (academic/industry, professional interest, ways of working…)o Loosely defined scopeo Unexpected outcomes

Scope

Scope

Outcome

Outcome

Outcome

Outcome


Measuring successRelinquishing control and empowering creativity

11

Predefined outcomeso Publicationso Collaborations

Unexpected outcomeso Individual interpretation

Prof. Luke O’Neill (Trinity College Dublin)

Publications

Collaborations

Immunology Catalyst

GSK Business Development

NewCo


o Diverse model driving Innovation

o Flexibility

o Building trust & productive relationships

o Collaboration

o Measuring success

o Evolving

Thank you to everyone who supports the GSK Immunolo gy Network & Thank you for listening

12

VisionTo enable GSK to lead in the field of immunology, to deliver the best science and the best medicines for patients by fully integrating immunology expertise between GSK and academia

The Immunology NetworkA unique industry-academia collaborative model


not all great minds need to think alike: a case study from ... · not all great minds need to think...

Documents